Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

OBJECTIVE: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, we characterise the role of tumour-initiating cells (T-ICs) and signalling pathways involved in sor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Tovar, Victoria, Cornella, Helena, Moeini, Agrin, Vidal, Samuel, Hoshida, Yujin, Sia, Daniela, Peix, Judit, Cabellos, Laia, Alsinet, Clara, Torrecilla, Sara, Martinez-Quetglas, Iris, Lozano, Juan José, Desbois-Mouthon, Christèle, Solé, Manel, Domingo-Domenech, Josep, Villanueva, Augusto, Llovet, Josep M
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600200/
https://ncbi.nlm.nih.gov/pubmed/26658144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2015-309501
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados